Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.57 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255214 | 0.93 | CDK4 (0.54) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3252610 | 0.89 | JAK2 (0.53) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3253066 | 0.86 | CDK4 (0.65) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3254769 | 0.82 | JAK2 (0.53) | KDRJAK2STK17AJAK3EGFR | |
| SCHEMBL3255998 | 0.82 | ACVR1 (0.64) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3257732 | 0.78 | CDK4 (0.61) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3252752 | 0.76 | CDK2 (0.57) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3258114 | 0.75 | ACVR1 (0.62) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL10192769 | 0.75 | JAK2 (0.59) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL3247393 | 0.75 | JAK2 (0.59) | CDK4CDK2KDRGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | CDK4 4/4885CDK2 22/4885KDR 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.